Generic Medicine Info
Indications and Dosage
Prostate cancer, Prostatic hyperplasia
Adult: 25 or 50 mg bid.

Menstrual disorders
Adult: As acetate: 2-10 mg/day alone or in combination with an oestrogen, either cyclically or continuously.

Part of combined oral contraceptive
Adult: 1-2 mg/day.
History of liver tumors, severe liver impairment, genital tract or breast carcinoma (unless progestogens are being used as part of the management of these conditions), arterial disease, undiagnosed vaginal bleeding and porphyria. Pregnancy, pregnancy testing, missed or incomplete abortion.
Special Precautions
CV or renal impairment, DM, asthma, epilepsy, migraine, other conditions which may be aggravated by fluid retention, history of depression. Lactation.
Adverse Reactions
GI and menstrual disturbances, wt gain, fluid retention, acne, melasma, allergic skin rashes, urticaria, mental depression, breast changes, altered libido, drowsiness/insomnia, hirsutism, alopecia, jaundice and anaphylactoid reactions (rare).
Drug Interactions
Clearance enhanced by enzyme-inducing drugs. Influence diabetic control of antidiabetic drugs. Avoid St. John's wort.
Potentially Fatal: Cyclosporin (risk of toxicity).
Lab Interference
Serum lipid profile and liver function tests alterations.
Description: Chlormadinone is a progestogen structurally related to progesterone, with some anti-androgenic activity. It is used alone or combined with an estrogen in the treatment of menstrual disorders. It has also been used in some countries in the management of prostate cancer.
MIMS Class
Oestrogens, Progesterones & Related Synthetic Drugs / Oral Contraceptives
Disclaimer: This information is independently developed by MIMS based on Chlormadinone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in